New 2023 vaccination schedules now available

Details for children and teenagers

For influenza vaccination, the Remarks section now includes new guidance on vaccinating people who are in close contact with severely immunocompromised patients who require a protected environment. For adults over 65, a preferential recommendation is made to give a high-dose flu vaccine.

For measles, mumps and rubella vaccination, a newly licensed vaccine with the trade name Priorix has been added to the table of vaccine abbreviations and trade names. Routine MMR vaccination consists of a two-dose series, with the first dose given at 12 to 15 months of age and the second dose at 4 to 6 years of age.

For pneumococcal vaccination, a new 15-valent pneumococcal conjugate vaccine with the trade name Vaxneuvance has been added to the cover page, all tables and the Notes section. All children should receive four doses of pneumococcal conjugate vaccine (PCV13 or PCV15) at 2, 4, 6, and 12 to 15 months.

For routine and catch-up vaccinations, the Remarks section indicates that PCV15 can be used interchangeably with the 13-valent pneumococcal conjugate vaccine in healthy children or children with underlying conditions. No additional PCV15 vaccine is indicated for children who have already completed their full, age-appropriate PCV13 series.

Finally, the appendix received several clarifying changes, with row changes for dengue fever vaccine, egg-based influenza vaccines, hepatitis B vaccines, human papillomavirus vaccine , MMR vaccines and varicella vaccine.

Details for adults

For hepatitis B vaccination, a three-dose vaccine with the trade name PreHevbrio has been added to the table of vaccine abbreviations and trade names; PreHevbrio is not recommended during pregnancy due to a lack of safety data. Additionally, clarifying language has been inserted in the Notes section indicating that persons aged 60 or over with known risk factors for hepatitis B infection should complete a series of hepatitis B vaccines, while people age 60 and older without known risk factors can complete a series of vaccines.

For influenza vaccination, new wording has been added to the Remarks section stating that for people age 65 and older who are having routine vaccinations, one of the following options is preferred:

• high dose inactivated influenza vaccine,
• recombinant quadrivalent influenza vaccine or
• quadrivalent inactivated influenza vaccine with adjuvant.

If none of these vaccines are available, any other age-appropriate influenza vaccine should be used.

Also for influenza vaccination, additional guidance has been provided for close contacts of severely immunocompromised patients who require a protected environment.

For pneumococcal vaccination, the Remarks section has undergone substantial changes on the use of PCV15 and PCV20 vaccines in people who have previously received other pneumococcal vaccines. The Notes section also contains links to the CDCs Guidance Document on the Pneumococcal Immunization Schedule for Adults and that of the agency PneumoRecs VaxAdvisor Mobile App to help clinicians determine which pneumococcal vaccines a person needs and when.

For polio vaccination, a new section in the Notes section discusses polio vaccination recommendations for adults at increased risk of poliovirus exposure.